Skip to main content
SpringerLink
Log in

Schizophrenia Still an Area of Unmet Therapeutic Need

Possibility of New Therapies by 2007

  • Emerging Technology
  • Published:
Pharmaceutical & Diagnostic Innovation

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II

Notes

  1. Risperidone (Johnson & Johnson), quetiapine (AstraZeneca) and olanzapine (Eli Lilly), respectively.

Reference

  1. Major Pharmaceuticals. Pharmaceutical therapeutic category forecasts: analysis of global top 10 therapeutic categories. New York: Lehman Brothers Global Equity Research, 2005

    Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schizophrenia Still an Area of Unmet Therapeutic Need. Pharmaceutical & Diagnostic Innovation 3, 10–12 (2005). https://doi.org/10.1007/BF03256983

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03256983

Keywords

Search

Navigation